CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 46 enrolled
Drug / intervention
BMS-790052drug
Likely dose
BMS-790052 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00859053
NCT00859053Phase 1Completed
CompareCT.gov

Single-Dose Pharmacokinetics of BMS-790052 in Subjects With Hepatic Impairment Compared to Healthy Subjects

Bristol-Myers Squibb·interventional·Posted Mar 10, 2009·Updated Oct 8, 2015

In Brief

A Phase 1 clinical trial evaluating BMS-790052 for Hepatic Insufficiency. Completed, enrolled 46 participants across 2 sites.

Detailed Summary

The purpose of this study is to assess the effects of hepatic impairment on the single dose pharmacokinetics of BMS-790052.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Insufficiency
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 10, 2009
Enrollment StartMar 1, 2009
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.3 years ago

Interventions

BMS-790052drug

Capsules, Oral, 30 mg, single dose, one day